Overall, these studies showed consistent results, indicating that elevated PVR expression is associated with decreased survival in patients with solid cancer, including lung cancer [8,28], esophageal cancer [9], cholangiocarcinoma [10], and breast cancer [12,29], and hematologic cancers, including AML [13]. This evidence concerns the gene PVR and breast cancer.